aibio
Distress ·
Cullinan unit ends MIT license for CLN-617 after dropping the program
Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026.
CGEM Cullinan Therapeutics, Inc.
Cullinan Therapeutics (CGEM) news
Latest Cullinan Therapeutics news
We have not published a story on Cullinan Therapeutics yet. When there is news, it will appear here.
Cullinan Therapeutics annual financials
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $187.4 million | $142.9 million |
| Net income (loss) | -$219.9 million | -$167.4 million |
| Cash from operations | -$175.8 million | -$145.3 million |
| Cash and equivalents | $88.3 million | $83.0 million |
| Short-term investments | $289.6 million | $316.0 million |
Questions about Cullinan Therapeutics
What is the ticker symbol of Cullinan Therapeutics?
Cullinan Therapeutics, Inc. trades under the ticker CGEM on NASDAQ.
Where is Cullinan Therapeutics listed?
Cullinan Therapeutics, Inc. is listed on NASDAQ.
What is the SEC CIK of Cullinan Therapeutics?
The SEC Central Index Key (CIK) for Cullinan Therapeutics, Inc. is 1789972. Its filings are on SEC EDGAR.
How many shares does Cullinan Therapeutics have outstanding?
64,354,694 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Cullinan Therapeutics listed under?
Our directory records Cullinan Therapeutics, Inc. under United States.
What does Cullinan Therapeutics do?
Our directory classifies Cullinan Therapeutics, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
What is the ISIN of Cullinan Therapeutics?
The ISIN recorded for Cullinan Therapeutics, Inc. is US2300311063.
Does aibio.space cover Cullinan Therapeutics?
aibio.space lists Cullinan Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Cullinan Therapeutics incorporated?
SEC records list its state or country of incorporation as DE.
Is Cullinan Therapeutics profitable?
Cullinan Therapeutics, Inc. reported a net loss of $219.9 million for the fiscal year ended Dec 31, 2025, and used $175.8 million of cash in operations, per its annual report to the SEC.
How much does Cullinan Therapeutics spend on research and development?
$187.4 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does Cullinan Therapeutics have?
$334.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest Cullinan Therapeutics (CGEM) stock news?
Our latest story on Cullinan Therapeutics, dated Nov 21, 2025: "Cullinan unit ends MIT license for CLN-617 after dropping the program". Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026. Source.
Is Cullinan Therapeutics in financial distress?
Our latest distress story, dated Nov 21, 2025: "Cullinan unit ends MIT license for CLN-617 after dropping the program". Cullinan Amber Corp. will return the licensed patent rights to MIT. The termination takes effect February 18, 2026. Source.
What is Cullinan Therapeutics's market cap?
We do not publish live share prices. In its annual report, Cullinan Therapeutics, Inc. put the market value of shares held by non-affiliates (public float) at $442.2 million as of Jun 30, 2025.
Investor discussion: Cullinan Therapeutics
Rules
- Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
- Say whether you hold the stock. Every post states long, short or no position.
- No paid or sponsored posts. Do not post for anyone who pays or rewards you.
- No buy or sell calls and no price targets.
- No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
- No personal details and no spam. No links at all for your first 7 days as a member.
Capital-markets timeline
- Distress
Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source
Stock chart
SEC filings and registration
- SEC name
- Cullinan Therapeutics, Inc.
- CIK
- 1789972
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) (2836)
- US tickers
- CGEM (Nasdaq)
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Business address
- ONE MAIN STREET, CAMBRIDGE, MA, 02142
- Phone
- 617-410-4650
- Shares outstanding
- 64,354,694 as of 2026-07-31 (10-Q filed 2026-08-06)
- Former names
- Cullinan Oncology, Inc.; Cullinan Management, Inc.; Cullinan Oncology, LLC
Recent filings
Listing details
- Company
- Cullinan Therapeutics, Inc.
- Ticker
- CGEM
- Listing
- NASDAQ
- Country or territory
- United States
- Business scope
- Pharmaceuticals: Major
- ISIN
- US2300311063
- Last quote in directory
- 2026-10-21
- Directory source
- Listing page
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction